Oramed Pharmaceuticals (OTC:ORMP.OB) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an oral insulin capsule currently in Phase 2 trials, the Company is seeking to revolutionize the treatment of diabetes.
Press Release

July 7, 2010

Oramed Pharmaceuticals and sanofi-aventis Enter into an Agreement for the Insulin supply of Oramed’s Oral Insulin Capsules

... read more »

June 28, 2010

Results of first exposure of Type 1 diabetes patients to Oramed's oral insulin and of the first-in-human study with its oral GLP-1 analog
... read more »  
Press Center | Terms & Conditions | Privacy Statement Design and programming by BIGDESIGN Creative Agency | All rights reserved © 2009 Oramed